Hydrophobic inactivation of influenza viruses confers preservation of viral structure with enhanced immunogenicity

Journal of Virology

Volumn 82, Issue 9, 2008, Pages 4612-4619

  Raviv, Yossef ^a,b,d   Blumenthal, Robert ^a   Tompkins, S Mark ^c   Humberd, Jennifer ^c   Hogan, Robert J ^c   Viard, Mathias ^a,b  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b SAIC FREDERICK INC   (United States)

^c UNIVERSITY OF GEORGIA   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,5 IODONAPHTHYLAZIDE; AZIDE; HEMAGGLUTININ; INFLUENZA VACCINE; SIALIDASE; UNCLASSIFIED DRUG; VIRUS ANTIGEN; VIRUS ENVELOPE PROTEIN; VIRUS VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHANNEL GATING; CONTROLLED STUDY; ENZYME LINKED IMMUNOSPOT ASSAY; EXPERIMENTAL MODEL; FLUORESCENCE RECOVERY AFTER PHOTOBLEACHING; IMMUNE RESPONSE; IMMUNOGENICITY; INFLUENZA; INFLUENZA VIRUS; MOUSE; NONHUMAN; PRIORITY JOURNAL; RETROVIRUS; SEROLOGY; VIRUS ENVELOPE; VIRUS INFECTION; VIRUS INFECTIVITY; VIRUS MORPHOLOGY;

ANIMALS; AZIDES; HYDROPHOBICITY; INFLUENZA VACCINES; MEMBRANE FUSION; MICE; ORTHOMYXOVIRIDAE; ORTHOMYXOVIRIDAE INFECTIONS; TREATMENT OUTCOME; VACCINES, INACTIVATED; VIRAL ENVELOPE PROTEINS; VIRUS INACTIVATION;

INFLUENZA A VIRUS; MURINAE; ORTHOMYXOVIRIDAE;

EID: 42449113988     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.02233-07     Document Type: Article

References (46)

1. Armstrong, R. T., A. S. Kushnir, and J. M. White. 2000. The transmembrane domain of influenza hemagglutinin exhibits a stringent length requirement to support the hemifusion to fusion transition. J. Cell Biol. 151:425-437.
2. Bardiya, N., and J. H. Bae. 2005. Influenza vaccines: recent advances in production technologies. Appl. Microbiol. Biotcchnol. 67:299-305.
3. Blumenthal, R., M. J. Clague, S. R. Durell, and R. M. Epand. 2003. Membrane fusion. Chem. Rev. 103:53-69.
4. Bravo, A., I. Gomez, J. Conde, C. Munoz-Garay, J. Sanchez, R. Miranda, M. Zhuang, S. S. Gill, and M. Soberon. 2004. Oligomerization triggers binding of a Bacillus thuringiensis Cry1Ab pore-forming toxin to aminopeptidase N receptor leading to insertion into membrane microdomains. Biochim. Biophys. Acta 1667:38-46.
5. Budowsky, E. I., S. E. Bresler, E. A. Friedman, and N. V. Zheleznova. 1981. Principles of selective inactivation of viral genome. 1. UV-induced inactivation of influenza virus. Arch. Virol. 68:239-247.
6. Budowsky, E. I., A. Smirnov Yu, and S. F. Shenderovich. 1993. Principles of selective inactivation of viral genome. VIII. The influence of beta-propiolactone on immunogenic and protective activities of influenza virus. Vaccine 11:343-348.
7. Bullough, P. A., F. M. Hughson, J. J. Skehel, and D. C. Wiley. 1994. Structure of influenza haemagglutinin at the pH of membrane fusion. Nature 371:37-43.
8. Clague, M. J., J. R. Knutson, R. Blumenthal, and A. Herrmann. 1991. Interaction of influenza hemagglutinin amino-terminal peptide with phospholipid vesicles: a fluorescence study. Biochemistry 30:5491-5497.
9. De Flora, S., and G. Badolati. 1973. Inactivation of A2-Hong Kong influenza virus by heat and by freeze-thawing. Comparison of untreated and gamma-irradiated preparations. Boll. Ist. Sieroter. Milan. 52:293-305.
10. De Flora, S., and G. Badolati. 1973. Thermal inactivation of untreated and gamma-irradiated A2-Aichi-2-68 influenza virus. J. Gen. Virol. 20:261-265.
11. Earp, L. J., S. E. Delos, H. E. Park, and J. M. White. 2005. The many mechanisms of viral membrane fusion proteins. Curr. Top. Microbiol. Immunol. 285:25-66.
12. Epand, R. F., C. M. Yip, L. V. Chernomordik, D. L. LeDuc, Y. K. Shin, and R. M. Epand. 2001. Self-assembly of influenza hemagglutinin: studies of ectodomain aggregation by in situ atomic force microscopy. Biochim. Biophys. Acta 1513:167-175.
13. Epstein, S. L. 2003. Control of influenza virus infection by immunity to conserved viral features. Expert Rev. Anti Infect. Ther. 1:627-638.
14. Epstein, S. L., W. P. Kong, J. A. Misplon, C. Y. Lo, T. M. Tumpey, L. Xu, and G. J. Nabel. 2005. Protection against multiple influenza A subtypes by vaccination with highly conserved nucleoprotein. Vaccine 23:5404-5410.
15. Epstein, S. L., T. M. Tumpey, J. A. Misplon, C. Y. Lo, L. A. Cooper, K. Subbarao, M. Renshaw, S. Sambhara, and J. M. Katz. 2002. DNA vaccine expressing conserved influenza virus proteins protective against H5N1 challenge infection in mice. Emerg. Infect. Dis. 8:796-801.
16. Finnegan, M. C., S. S. Satinder, E. H. Cho, D. L. Guiffre, S. Lockett, A. H. Merill, Jr., and R. Blumenthal. 2007. Sphingomyelinase restricts the lateral diffusion of CD4 and inhibits human immunodeficiency virus fusion. J. Biol. Chem. 81:5294-5304.
17. Fiore, A. E., D. K. Shay, P. Haber, J. K. Iskander, T. M. Uyeki, G. Mootrey, J. S. Bresee, and N. J. Cox. 2007. Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2007. MMWR Recommend. Rep. 56:1-54.
18. Haan, L., W. R. Verweij, M. Holtrop, R. Brands, G. J. van Scharrenburg, A. M. Palache, E. Agsteribbe, and J. Wilschut. 2001. Nasal or intramuscular immunization of mice with influenza subunit antigen and the B subunit of Escherichia coli heat-labile toxin induces IgA- or IgG-mediated protective mucosal immunity. Vaccine 19:2898-2907.
19. Hovden, A. O., R. J. Cox, and L. R. Haaheim. 2005. Whole influenza virus vaccine is more immunogenic than split influenza virus vaccine and induces primarily an IgG2a response in BALB/c mice. Scand. J. Immunol. 62:36-44.
20. Hovden, A. O., R. J. Cox, A. Madhun, and L. R. Haaheim. 2005. Two doses of parenterally administered split influenza virus vaccine elicited high serum IgG concentrations which effectively limited viral shedding upon challenge in mice. Scand. J. Immunol. 62:342-352.
21. Kemble, G. W., T. Danieli, and J. M. White. 1994. Lipid-anchored influenza hemagglutinin promotes hemifusion, not complete fusion. Cell 76:383-391.
22. Korte, T., K. Ludwig, F. P. Booy, R. Blumenthal, and A. Herrmann. 1999. Conformational intermediates and fusion activity of influenza virus hemagglutinin. J. Virol. 73:4567-4574.
23. Laver, W. G. 1978. Crystallization and peptide maps of neuraminidase "heads" from H2N2 and H3N2 influenza virus strains. Virology 86:78-87.
24. Lippincott-Schwartz, J., E. Snapp, and A. Kenworthy. 2001. Studying protein dynamics in living cells. Nat. Rev. Mol. Cell Biol. 2:444-456.
25. Lowy, R. J., G. A. Vavrina, and D. D. LaBarre. 2001. Comparison of gamma and neutron radiation inactivation of influenza A virus. Antivir. Res. 52:261-273.
26. Melikyan, G. B., S. A. Brener, D. C. Ok, and F. S. Cohen. 1997. Inner but not outer membrane leaflets control the transition from glycosylphosphatidylinositol-anchored influenza hemagglutinin-induced hemifusion to full fusion. J. Cell Biol. 136:995-1005.
27. Nir, S., F. Nicol, and F. C. Szoka, Jr. 1999. Surface aggregation and membrane penetration by peptides: relation to pore formation and fusion. Mol. Membr. Biol. 16:95-101.
28. Noad, R., and P. Roy. 2003. Virus-like particles as immunogens. Trends Microbiol. 11:438-444.
29. 125I]iodonaphthylazide. J. Biol. Chem. 269:14614-14619.
30. Popik, W., and T. M. Alee. 2004. CD4 receptor localized to non-raft membrane microdomains supports HIV-1 entry. Identification of a novel raft localization marker in CD4. J. Biol. Chem. 279:704-712.
31. Puri, A., F. P. Booy, R. W. Doms, J. M. White, and R. Blumenthal. 1990. Conformational changes and fusion activity of influenza virus hemagglutinin of the H2 and H3 subtypes: effects of acid pretreatment. J. Virol. 64:3824-3832.
32. Quan, F.-S., C. Huang, R. W. Compans, and S.-M. Kang. 2007. Virus-like particle vaccine induces protective immunity against homologous and heterologous strains of influenza virus. J. Virol. 81:3514-3524.
33. Raviv, Y., M. Viard, J. Bess, Jr., and R. Blumenthal. 2002. Quantitative measurement of fusion of HIV-1 and SIV with cultured cells using photosensitized labeling. Virology 293:243-251.
34. Raviv, Y., M. Viard, J. W. Bess, Jr., E. Chertova, and R. Blumenthal. 2005. Inactivation of retroviruses with preservation of structural integrity by targeting the hydrophobic domain of the viral envelope. J. Virol. 79:12394-12400.
35. Redfield, D. C., D. D. Richman, M. N. Oxman, and L. H. Kronenberg. 1981. Psoralen inactivation of influenza and herpes simplex viruses and of virus-infected cells. Infect. Immun. 32:1216-1226.
36. Rose, G. W., and C. L. Cooper. 2006. Fluarix, inactivated split-virus influenza vaccine. Expert Opin. Biol. Ther. 6:301-310.
37. Stegmann, T., F. P. Booy, and J. Wilschut. 1987. Effects of low pH on influenza virus. Activation and inactivation of the membrane fusion capacity of the hemagglutinin. J. Biol. Chem. 262:17744-17749.
38. Stephenson, I., M. C. Zambon, A. Rudin, A. Colegate, A. Podda, R. Bugarini, G. Del Giudice, A. Minutello, S. Bennington, J. Holmgren, K. H. Mills, and K. G. Nicholson. 2006. Phase I evaluation of intranasal trivalent inactivated influenza vaccine with nontoxigenic Escherichia coli enterotoxin and novel biovector as mucosal adjuvants, using adult volunteers. J. Virol. 80:4962-4970.
39. Tamura, S., T. Tanimoto, and T. Kurata. 2005. Mechanisms of broad cross-protection provided by influenza virus infection and their application to vaccines. Jpn. J. Infect. Dis. 58:195-207.
40. Tumpey, T. M., M. Renshaw, J. D. Clements, and J. M. Katz. 2001. Mucosal delivery of inactivated influenza vaccine induces B-cell-dependent heterosubtypic cross-protection against lethal influenza A H5N1 virus infection. J. Virol. 75:5141-5150.
41. Ulmer, J. B., J. J. Donnelly, S. E. Parker, G. H. Rhodes, P. L. Felgner, V. J. Dwarki, S. H. Gromkowski, R. R. Deck, C. M. DeWitt, A. Friedman, et al. 1993. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 259:1745-1749.
42. Wood, J. M., and J. S. Robertson. 2004. From lethal virus to life-saving vaccine: developing inactivated vaccines for pandemic influenza. Nat. Rev. Microbiol. 2:842-847.
43. Wright, P. F., G. Neumann, and Y. Kawaoka. 2007. Orthomyxoviruses, p. 1692-1740. In D. M. Knipe, P. M. Howley, D. E. Griffin, M. A. Martin, R. A. Lamb, B. Roizman, and S. E. Straus (ed.), Fields virology, 5th ed., vol. 2. Lippincott Williams & Wilkins, Philadelphia, PA.
44. Yao, Q., Z. Bu, A. Vzorov, C. Yang, and R. W. Compans. 2003. Virus-like particle and DNA-based candidate AIDS vaccines. Vaccine 21:638-643.
45. Zemel, A., A. Ben-Shaul, and S. May. 2005. Perturbation of a lipid membrane by amphipathic peptides and its role in pore formation. Eur. Biophys. J. 34:230-242.
46. Zheleznova, N. V. 1982. Method of influenza virus UV inactivation applied to the manufacture of an inactivated chromatographic influenza vaccine. Tr. Inst. Im. Pastera 59:81-88. (In Russian.)